查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2019565

Apixaban全球市場規模、佔有率、趨勢和成長分析報告，2026-2034年

Global Apixaban Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 119 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

Apixaban市場預計將從 2025 年的 37.1 億美元成長到 2034 年的 84.7 億美元，2026 年至 2034 年的複合年成長率為 9.62%。

由於心血管疾病和血栓性栓塞症的盛行率不斷上升，全球Apixaban市場正經歷強勁成長。Apixaban是一種口服抗凝血劑，廣泛用於預防心房顫動和深部靜脈栓塞等疾病患者的中風和血栓形成。人口老化和人們對抗凝血治療認知的不斷提高是推動市場擴張的主要因素。此外，從傳統治療方法轉向新型口服抗凝血劑的轉變也促進了深層靜脈栓塞症的普及。

成長要素包括Apixaban的臨床優勢，例如與傳統抗凝血劑相比，出血風險更低且無需定期監測。醫療基礎設施的擴建和先進藥物可近性的提高也促進了市場成長。此外，正在進行的研究和臨床試驗正在探索新的治療應用，從而提升了市場潛力。製藥公司正積極致力於拓展產品系列併擴大企業發展。

隨著對高效便捷的抗凝血治療的需求不斷成長，Apixaban市場預計將穩步成長。學名藥的研發將進一步提高藥物的可近性和可負擔性。在新興市場，不斷提高的健康意識有望創造巨大的成長機會。此外，心血管疾病治療和預防領域的持續進步也將推動市場的長期擴張。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球Apixaban市場：按類型分類

  • 市場分析、洞察與預測
  • 膠囊
  • 藥片

第5章：全球Apixaban市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 診所
  • 零售藥房
  • 網路藥房

第6章 全球Apixaban市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Fresenius Kabi AG
    • Bristol Myers Squibb Company
    • Yino Pharma Limited
    • Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd
    • Mylan NV
    • Eisai Co. Ltd
    • Sanofi
    • Aspen Holdings
    • Hikma Pharmaceuticals PLC
    • Hebei Changshan Biochemical Pharmaceutical Co. Ltd
    • Abbott
    • Pfizer Inc
    • F. Hoffmann-La Roche Ltd
簡介目錄
Product Code: VMR11216577

The Apixaban Market size is expected to reach USD 8.47 Billion in 2034 from USD 3.71 Billion (2025) growing at a CAGR of 9.62% during 2026-2034.

The global apixaban market is experiencing strong growth due to the increasing prevalence of cardiovascular diseases and thromboembolic disorders. Apixaban, an oral anticoagulant, is widely used to prevent stroke and blood clots in patients with conditions such as atrial fibrillation and deep vein thrombosis. The growing aging population and rising awareness about anticoagulant therapies are key factors driving market expansion. Additionally, the shift toward novel oral anticoagulants over traditional therapies is supporting increased adoption.

Key growth drivers include the clinical advantages of apixaban, such as reduced risk of bleeding and no requirement for routine monitoring compared to older anticoagulants. The expansion of healthcare infrastructure and increasing access to advanced medications are also contributing to market growth. Furthermore, ongoing research and clinical trials are exploring new therapeutic applications, enhancing its market potential. Pharmaceutical companies are actively focusing on expanding their product portfolios and geographic reach.

Looking ahead, the apixaban market is expected to grow steadily with increasing demand for effective and convenient anticoagulant therapies. The development of generic versions will further improve accessibility and affordability. Emerging markets are likely to provide significant growth opportunities due to rising healthcare awareness. Additionally, continuous advancements in cardiovascular treatment and preventive care will drive long-term market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Capsule
  • Tablets

By End User

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Fresenius Kabi AG, Bristol Myers Squibb Company, Yino Pharma Limited, Nanjing Jianyou Biochemical Pharmaceutical Co Ltd, Mylan NV, Eisai Co Ltd, Sanofi, Aspen Holdings, Hikma Pharmaceuticals PLC, Hebei Changshan Biochemical Pharmaceutical Co Ltd, Abbott, Pfizer Inc, F HoffmannLa Roche Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL APIXABAN MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Capsule Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL APIXABAN MARKET: BY END USER 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End User
  • 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL APIXABAN MARKET: BY REGION 2022-2034 (USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Type
    • 6.2.2 By End User
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Type
    • 6.3.2 By End User
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Type
    • 6.4.2 By End User
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Type
    • 6.5.2 By End User
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Type
    • 6.6.2 By End User
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL APIXABAN INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Fresenius Kabi AG
    • 8.2.2 Bristol Myers Squibb Company
    • 8.2.3 Yino Pharma Limited
    • 8.2.4 Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd
    • 8.2.5 Mylan N.V
    • 8.2.6 Eisai Co. Ltd
    • 8.2.7 Sanofi
    • 8.2.8 Aspen Holdings
    • 8.2.9 Hikma Pharmaceuticals PLC
    • 8.2.10 Hebei Changshan Biochemical Pharmaceutical Co. Ltd
    • 8.2.11 Abbott
    • 8.2.12 Pfizer Inc
    • 8.2.13 F. Hoffmann-La Roche Ltd